Footnotes

• Contributors Conception and design, administrative support, provision of study materials or patients, collection and assembly of data, data analysis and interpretation, manuscript writing, final approval of manuscript: all authors.

• Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

• Competing interests HT: Gilead: Honoraria; Takeda: Consultancy, Honoraria; Celgene: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees, Research Funding; Karyopharm: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees; Roche: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees, Research Funding; Janssen: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees; Immunogen: Honoraria. VC: Gilead: Honoraria—Amgen: Honoraria—BMS: Honoraria; Roche: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees. FJ: Roche: Honoraria; Janssen: Honoraria; Celgen: Honoraria.

• Patient consent for publication Not required.

• Provenance and peer review Not commissioned; externally peer reviewed.